Literature DB >> 35482954

Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.

Giulia Iannelli, Ciro Milite, Nils Marechal1,2,3,4, Vincent Cura1,2,3,4, Luc Bonnefond1,2,3,4, Nathalie Troffer-Charlier1,2,3,4, Alessandra Feoli, Donatella Rescigno, Yalong Wang5, Alessandra Cipriano, Monica Viviano, Mark T Bedford5, Jean Cavarelli1,2,3,4, Sabrina Castellano, Gianluca Sbardella.   

Abstract

Protein arginine methyltransferases (PRMTs) are important therapeutic targets, playing a crucial role in the regulation of many cellular processes and being linked to many diseases. Yet, there is still much to be understood regarding their functions and the biological pathways in which they are involved, as well as on the structural requirements that could drive the development of selective modulators of PRMT activity. Here we report a deconstruction-reconstruction approach that, starting from a series of type I PRMT inhibitors previously identified by us, allowed for the identification of potent and selective inhibitors of PRMT4, which regardless of the low cell permeability show an evident reduction of arginine methylation levels in MCF7 cells and a marked reduction of proliferation. We also report crystal structures with various PRMTs supporting the observed specificity and selectivity.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35482954      PMCID: PMC9469100          DOI: 10.1021/acs.jmedchem.2c00252

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  128 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

3.  Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity.

Authors:  Donghang Cheng; Sergio Valente; Sabrina Castellano; Gianluca Sbardella; Roberto Di Santo; Roberta Costi; Mark T Bedford; Antonello Mai
Journal:  J Med Chem       Date:  2011-06-13       Impact factor: 7.446

4.  Arginine Demethylation of G3BP1 Promotes Stress Granule Assembly.

Authors:  Wei-Chih Tsai; Sitaram Gayatri; Lucas C Reineke; Gianluca Sbardella; Mark T Bedford; Richard E Lloyd
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

5.  1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).

Authors:  Eric Therrien; Guillaume Larouche; Sukhdev Manku; Martin Allan; Natalie Nguyen; Sylvia Styhler; Marie-France Robert; Anne-Christine Goulet; Jeffrey M Besterman; Hannah Nguyen; Amal Wahhab
Journal:  Bioorg Med Chem Lett       Date:  2009-10-02       Impact factor: 2.823

6.  Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.

Authors:  Heng Hong; Chinghai Kao; Meei-Huey Jeng; John N Eble; Michael O Koch; Thomas A Gardner; Shaobo Zhang; Lang Li; Chong-Xian Pan; Zhiqiang Hu; Gregory T MacLennan; Liang Cheng
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

7.  Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

Authors:  Tram Huynh; Zhong Chen; Suhong Pang; Jieping Geng; Tiziano Bandiera; Simona Bindi; Paola Vianello; Fulvia Roletto; Sandrine Thieffine; Arturo Galvani; Wayne Vaccaro; Michael A Poss; George L Trainor; Matthew V Lorenzi; Marco Gottardis; Lata Jayaraman; Ashok V Purandare
Journal:  Bioorg Med Chem Lett       Date:  2009-04-22       Impact factor: 2.823

8.  A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion.

Authors:  Xiao-Chuan Cai; Tuo Zhang; Eui-Jun Kim; Ming Jiang; Ke Wang; Junyi Wang; Shi Chen; Nawei Zhang; Hong Wu; Fengling Li; Carlo C Dela Seña; Hong Zeng; Victor Vivcharuk; Xiang Niu; Weihong Zheng; Jonghan P Lee; Yuling Chen; Dalia Barsyte; Magda Szewczyk; Taraneh Hajian; Glorymar Ibáñez; Aiping Dong; Ludmila Dombrovski; Zhenyu Zhang; Haiteng Deng; Jinrong Min; Cheryl H Arrowsmith; Linas Mazutis; Lei Shi; Masoud Vedadi; Peter J Brown; Jenny Xiang; Li-Xuan Qin; Wei Xu; Minkui Luo
Journal:  Elife       Date:  2019-10-28       Impact factor: 8.140

9.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.

Authors:  Alessio Ciulli; Glyn Williams; Alison G Smith; Tom L Blundell; Chris Abell
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

10.  CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Authors:  Sarah M Greenblatt; Na Man; Pierre-Jacques Hamard; Takashi Asai; Daniel Karl; Concepcion Martinez; Daniel Bilbao; Vasileios Stathias; Anna M Jermakowicz; Stephanie Duffort; Madhavi Tadi; Ezra Blumenthal; Samantha Newman; Ly Vu; Ye Xu; Fan Liu; Stephan C Schurer; Michael T McCabe; Ryan G Kruger; Mingjiang Xu; Feng-Chun Yang; Daniel G Tenen; Justin Watts; Francisco Vega; Stephen D Nimer
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

View more
  2 in total

1.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-09

2.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2022-10-13       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.